SILENCE THER. (SLN)

 

Latest News

Holding in Company

RNS Number: 6173R Silence Therapeutics PLC 22 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Th...

Holding in Company

RNS Number: 6117R Silence Therapeutics PLC 22 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Th...

Holding in Company

RNS Number: 6010R Silence Therapeutics PLC 22 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence T...

Holding in Company

RNS Number: 5998R Silence Therapeutics PLC 22 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence T...

All News

DateHeadlineSource
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
20-09-17Second Price Monitoring ExtnRNS
20-09-17Price Monitoring ExtensionRNS
13-09-17Second Price Monitoring ExtnRNS
13-09-17Price Monitoring ExtensionRNS
11-09-17Silence patents approvedStockMarketWire
11-09-17Further Strengthens US Patent EstateRNS
08-09-17Second Price Monitoring ExtnRNS
08-09-17Price Monitoring ExtensionRNS
06-09-17Silence Therapeutics makes progress on drug pipelineStockMarketWire
06-09-17Interim results for six months ended 30 June 2017RNS
04-09-17Notice of Interim ResultsRNS
23-08-17Save the Date: Capital Markets Event 14 NovemberRNS
17-08-17Replacement - Holding(s) in CompanyRNS
17-08-17Director/PDMR ShareholdingRNS
15-08-17Two further US patents to be grantedRNS
03-08-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
03-08-17Director/PDMR ShareholdingRNS
31-07-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
31-07-17Director/PDMR ShareholdingRNS
31-07-17Silence Therapeutics updates on expansion of its patent estateStockMarketWire
31-07-17Holding(s) in CompanyRNS
31-07-17US patent to be grantedRNS
27-07-17Licensee Quark Announces Positive AKI ResultsRNS
24-07-17Silence Strengthens US Patent EstateRNS
24-07-17Presenting at Canaccord Genuity Growth ConferenceRNS
14-07-17CEO Ali Mortazavi appointed Chairman of UltromicsRNS
10-07-17Silence Therapeutics notes Alnylam statementStockMarketWire
10-07-17IP updateRNS
03-07-17Issue of claim in the UK High CourtsRNS
03-07-17Change of AdviserRNS
29-06-17Holding(s) in CompanyRNS
06-06-17Result of AGMRNS
01-06-17Hiring of Chief Operating OfficerRNS
30-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
30-05-17Silence Continued Expansion of IPRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory